Cerulean Pharma Inc (NASDAQ:CERU) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: January 11, 2017
Zacks Investment Research has downgraded Cerulean Pharma Inc (NASDAQ:CERU) to Hold in a statement released on Wednesday January 11, 2017.
On 03/09/2016, JP Morgan released a statement for Cerulean Pharma Inc (NASDAQ:CERU) bumped down the target price from $16.00 to $9.00 that suggested an upside of 3.17%.
Boasting a price of $0.80, Cerulean Pharma Inc (NASDAQ:CERU) traded -3.96% lower on the day. With the last stock price close down -41.28% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.05% over the date range. Cerulean Pharma Inc has recorded a 50-day average of $0.76 and a two hundred day average of $1.36. Volume of trade was down over the average, with 183,594 shares of CERU changing hands under the typical 634,992
See Chart Below
Cerulean Pharma Inc has a 52 week low of $0.63 and a 52 week high of $4.33 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 7 firms have issued a report on the stock. The consensus target price is $9.43 with 4 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
General Information About Cerulean Pharma Inc (NASDAQ:CERU)
Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company's product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.